Please login to the form below
KeyNote-158 trial
This page shows the latest KeyNote-158 trial news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda receives FDA approval for advanced endometrial cancer
The approval was based on new data from the KEYNOTE-158 trial, with 90 patients with unresectable or metastatic endometrial carcinoma being enrolled. ... Dr David O’Malley, division of gynaecologic oncology at The Ohio State University Wexner Medical
Latest news
-
More good news, and some bad, for Merck’s Keytruda
The application is for accelerated approval based on the results of the KEYNOTE-158 trial, which showed that Keytruda, given as a monotherapy to SCLC patients whose cancer had progressed despite ... Liver failure. On the downside, Merck also revealed
More from news
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
AMICULUM
AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
